ライフサイエンスコーパス: vision loss

1 enic edema and neural tissue damage, causing vision loss.

2 on, prevented cell death, and protected from vision loss.

3 tural changes precede clinically significant vision loss.

4 o analyze potential predictors for permanent vision loss.

5 the influence of baseline patient factors on vision loss.

6 mended comprehensive eye care for preventing vision loss.

7 vastating ocular condition causing permanent vision loss.

8 on; only half were aware of smoking risks on vision loss.

9 ients (22%) and 6 eyes (13%) had significant vision loss.

10 of neural plasticity in the context of adult vision loss.

11 retinopathy is a major cause of irreversible vision loss.

12 lion cells (RGCs), resulting in irreversible vision loss.

13 untreatable and leads to partial or complete vision loss.

14 ceptor degeneration resulting in progressive vision loss.

15 glaucoma patients with different degrees of vision loss.

16 ompromises corneal transparency resulting in vision loss.

17 acula and/or peripapillary region leading to vision loss.

18 ammatory condition associated with permanent vision loss.

19 analyses) were used to estimate freedom from vision loss.

20 cess as their renal disease, and neither had vision loss.

21 urological deficits, hearing impairment, and vision loss.

22 between ffERG abnormalities and the rate of vision loss.

23 nked to time since diagnosis and location of vision loss.

24 ergetics, and mutations in complex I lead to vision loss.

25 and its recurrence may lead to irreversible vision loss.

26 e infection, device extrusion, and permanent vision loss.

27 es with central-involved DME that has caused vision loss.

28 are associated with more frequent all-cause vision loss.

29 actors and prevent further complications and vision loss.

30 rget in the mechanism of complex 1-deficient vision loss.

31 The most common symptom was vision loss.

32 degenerations (AMDs) are important causes of vision loss.

33 hat causes retinal degeneration and eventual vision loss.

34 g their head and eyes towards known areas of vision loss.

35 ay acquire vestibular as well as hearing and vision loss.

36 erent coping strategies in response to their vision loss.

37 al vascular diseases are important causes of vision loss.

38 en in analyses adjusting for the severity of vision loss.

39 tions are rare but can result in significant vision loss.

40 re for patients who have already experienced vision loss.

41 iest phases of DR when treatment can prevent vision loss.

42 order to determine the cause of unexplained vision loss.

43 ter mitochondrial defects that contribute to vision loss.

44 dB; larger negative values indicate greater vision loss.

45 roximately 10% of CATT patients had sporadic vision loss.

46 therapy to prevent progressive glaucomatous vision loss.

47 .5%) were the most common cause of permanent vision loss.

48 tentially leading to irreversible and severe vision loss.

49 l break formation and to prevent the central vision loss.

50 mporal relationship between RNFL decline and vision loss.

51 s, it is considered a surrogate endpoint for vision loss.

52 ntral to the pathogenesis of major causes of vision loss.

53 and/or therapeutic approaches for combating vision loss.

54 eading genetic cause of combined hearing and vision loss.

55 Prevalence and main causes of vision loss.

56 asing numbers is needed to address avoidable vision loss.

57 t undesirable effects including, ironically, vision loss.

58 e past year (OR, 1.61) were risk factors for vision loss.

59 cular dystrophies (MDs) are a major cause of vision loss.

60 an lead to iatrogenic glaucoma and permanent vision loss.

61 r disease or trauma that result in permanent vision loss.

62 acts to relatively inexpensive prevention of vision loss.

63 omplex retinal disease that leads to central vision loss.

64 tinal degenerations that lead to progressive vision loss.

65 that encodes for nephrocystin-5 (NPHP5), had vision loss.

66 sionally the cornea is infected resulting in vision loss.

67 2 Humphrey visual fields, or the duration of vision loss.

68 orm of advanced AMD and leads to significant vision loss.

69 ation (AMD) is a major cause of irreversible vision loss.

70 ng causes of retinal disease and age-related vision loss.

71 CS shows potential to help prevent avoidable vision loss.

72 posure symptoms (8 malignancies), unilateral vision loss (3 malignancies), and facial nerve paresis (

73 sual sensory processing, introducing central vision loss (a scotoma).

74 G is insufficient for predicting the rate of vision loss, abnormalities can develop.

75 eyes with diabetic macular edema (DME) with vision loss after macular laser photocoagulation is clin

76 eyes with diabetic macular edema (DME) with vision loss after macular laser photocoagulation is clin

77 ic outcomes in eyes experiencing substantial vision loss after macular laser photocoagulation treatme

78 ic outcomes in eyes experiencing substantial vision loss after macular laser photocoagulation treatme

79 g on an endoscope lens capable of preventing vision loss after repeated submersions in blood and mucu

80 Vision loss also strengthened inhibitory synaptic functi

81 ting myopia-related ocular complications and vision loss among almost 1 billion people with high myop

82 Perception of vision loss among patients with glaucoma may be associat

83 D) is the most common cause of uncorrectable vision loss among the elderly in developed countries.

84 acular edema is one of the leading causes of vision loss among working-age adults in the United State

85 should be considered in patients with acute vision loss and abnormalities on NIR-REF imaging, especi

86 cient model that leads to RGC loss and rapid vision loss and allows for streamlined testing of potent

87 d prompt initiation of treatment may prevent vision loss and blindness in affected patients.

88 ay a significant role in preventing glaucoma vision loss and blindness in people of African descent l

89 f normal tension glaucoma, a common cause of vision loss and blindness that occurs without grossly ab

90 of individuals from experiencing unnecessary vision loss and blindness, decrease associated costs to

91 ints are needed that reliably predict future vision loss and can be easily measured.

92 Cep290(ko/ko) mice exhibit early vision loss and die from hydrocephalus.

93 serious damages in the eye leading to severe vision loss and even blindness if left untreated.

94 macula constitute a major cause of incurable vision loss and exhibit considerable clinical and geneti

95 ibed OCT finding associated with significant vision loss and is an essential element of a novel OCT-b

96 e factors mediating the relationship between vision loss and mobility are needed to better understand

97 While ELOVL4 mutations are linked to vision loss and neuronal dysfunctions, the roles of VLC-

98 nting characteristics and incidence rates of vision loss and ocular complications in a cohort of poly

99 Noninfectious uveitis results in vision loss and ocular complications without adequate tr

100 ay have worse visual outcomes with increased vision loss and ocular complications.

101 Given recent treatment advances in reducing vision loss and preserving vision in persons with DME, i

102 -related macular degeneration causes central vision loss and represents a major health problem in eld

103 outcome measures included incidence rates of vision loss and retinal detachment (RD).

104 eceived anti-VEGF therapy to prevent further vision loss and retinal neovascularization due to extens

105 The relationship between functional vision loss and structural changes of the optic nerve he

106 e performed to calculate cumulative rates of vision loss and to assess risk factors for vision loss,

107 VL was associated with greater acceptance of vision loss and use of instrumental coping, good social

108 de severe neurological deficits, hearing and vision loss, and intrauterine growth restriction.

109 RD confers the greatest risk of incident vision loss, and once 25% or more of the retina is invol

110 ally evident radiation maculopathy, moderate vision loss, and poor visual acuity less frequently over

111 These diseases cause irreversible vision loss, and provide a significant health and econom

112 Low IOP after trabeculectomy, reoperation, vision loss, and surgical failure.

113 mes that were examined included reoperation, vision loss, and surgical failure.

114 mblyopia results in permanent, uncorrectable vision loss, and the benefits of screening and treatment

115 hemes coded and categorized as the impact of vision loss, and understandings of the disease and its m

116 udy is to determine if (AMD) and AMD-related vision loss are associated with fear of falling, an impo

117 complication and should include significant vision loss as a possible rare complication.

118 insights into the molecular pathogenesis of vision loss associated with an RPE65 point mutation.

119 and offer a new rationale and mechanism for vision loss associated with genetic defects in Tulp1.

120 em further neurodegeneration and concomitant vision loss associated with geographic atrophy of the ma

121 is required to validate the implied risk of vision loss associated with these terms.

122 beta-2 microglobulin and Cx3cr1, and during vision loss at P31 (B2m, Tlr 2, 3, 4, C1qa, Cx3cr1 and F

123 l basis could reduce drastically the rate of vision loss attributed to DR.

124 ecessitate the development of treatments for vision loss because of endothelial dysfunction that do n

125 in the eye and the brain before substantial vision loss can be detected clinically using current tes

126 apy progress has raised the possibility that vision loss caused by inherited retinal degeneration can

127 ng the dimerization of vitamin A can prevent vision loss caused by Stargardt disease and other retino

128 We report a case of reversible vision loss complicating AIDS-related CM with a normal I

129 Most patients with AMD-related central vision loss continue to drive, but demonstrate significa

130 degeneration (AMD), a leading contributor of vision loss, currently lacks comprehensive treatment.

131 data sources permitted modelling of cause of vision loss data from 1990 to 2015, further disaggregati

132 Subjects with vision loss demonstrate greater intra- and intervisit va

133 rovement as well as reduction of the risk of vision loss due to Age-Related Macular Degeneration (AMD

134 ry to retinal vein occlusion (RVO) can cause vision loss due to blockage of the central retinal vein

135 Preventable vision loss due to cataract (reversible with surgery) an

136 requiring intervention (P = 0.049) and less vision loss due to glaucoma progression (P = 0.046).

137 ghted controls and participants with central vision loss due to macular degeneration (MD).

138 from 7 patients experienced a new episode of vision loss during the study and 45 eyes (82%) from 39 p

139 treatment would aid in reducing the rate of vision loss, enabling timely and accurate diagnoses.

140 Corneal edema and subsequent vision loss ensues when endothelial cell density decreas

141 Irreversible vision loss entails a challenging medical condition in w

142 as are neurodegenerative diseases that cause vision loss, especially in the elderly.

143 etween the baseline visit and first event of vision loss event was greatest in the superior (-14%) an

144 There were 143 sporadic vision loss events in 122 of 1185 patients (10.3%).

145 Vision loss following episcleral brachytherapy for uveal

146 ine risk calculator was developed to predict vision loss following episcleral brachytherapy.

147 Causes of vision loss for children with vision impairment (recorde

148 lls and fear of falling for individuals with vision loss from AMD are important goals for future work

149 entions to increase their chance of avoiding vision loss from AMD.

150 age disorder in which patients suffer severe vision loss from associated retinopathy.

151 Vision loss from central retinal artery occlusion occurr

152 ong-term benefit of NSAID therapy to prevent vision loss from CME at 3 months or more after cataract

153 A total of 483 adults with vision loss from DME treated with ranibizumab were inclu

154 lectomy was associated with a higher rate of vision loss from glaucoma (HR = 3.25, P = .04).

155 sed to screen for moderate to severe central vision loss from glaucoma.

156 iate between young children with and without vision loss from OPGs.

157 Children experiencing vision loss from their optic pathway gliomas frequently

158 pathway gliomas (OPGs) frequently experience vision loss from their tumors.

159 erity of systemic and ocular toxicities, and vision loss >/=15 ETDRS letters.

160 r of people affected by the common causes of vision loss has increased substantially as the populatio

161 oroidal neovascular stage before substantial vision loss has occurred and to consider dietary supplem

162 ntify patients with nvAMD before substantial vision loss has occurred may reduce the amount of visual

163 Many ocular syphilis patients experienced vision loss; however, most improved posttreatment.

164 ulitis was associated with a reduced risk of vision loss (HR 0.36, 95% CI 0.15-0.82, P = .01).

165 hazard ratio [HR], 0.73; 95% CI, 0.32-1.68), vision loss (HR, 1.77; 95% CI, 0.81-3.88) or surgical fa

166 A total of 36 patients with vision loss in 1 eye attributable to macular edema follo

167 genic process that critically contributes to vision loss in age-related macular degeneration, is uncl

168 The overall prevalence of vision loss in Australia was 6.6% (95% confidence interv

169 Macular edema is the leading cause of vision loss in bilateral chronic noninfectious posterior

170 whether inflammation accompanies progressive vision loss in certain subtypes.

171 his study aimed at identifying the causes of vision loss in children attending the national referral

172 neovascularization (CNV) is a major cause of vision loss in chronic central serous chorioretinopathy

173 The vision loss in CLN5 deficient mice is primarily caused b

174 (AMD)-the main cause of irreversible severe vision loss in developed countries-given the suggestion

175 r degeneration (AMD) is the leading cause of vision loss in developed countries.

176 ic macular edema (DME) is the major cause of vision loss in diabetic persons.

177 pathological and clinical stages leading to vision loss in diabetic retinopathy (DR) are highlighted

178 or neovascular eye disease, a major cause of vision loss in diabetic retinopathy and age-related macu

179 ly contributing to retinal complications and vision loss in diabetic retinopathy.

180 the blood-retinal barrier (BRB) is linked to vision loss in DR and AMD.

181 uding macular edema (ME), a leading cause of vision loss in DR.

182 d about the prevalence and nature of central vision loss in early glaucoma.

183 rehabilitative services to address childhood vision loss in Eritrea.

184 This study explored the causes of vision loss in Eritrean children using hospital based da

185 ributes to macular edema, a leading cause of vision loss in eye pathologies such as diabetic retinopa

186 2: 45 year-old woman was referred for recent vision loss in her left eye.

187 ed by late-onset and progressive hearing and vision loss in humans.

188 eal structural abnormalities associated with vision loss in incontinentia pigmenti (IP).

189 ptor degeneration is a cause of irreversible vision loss in incurable blinding retinal diseases inclu

190 nwide survey on the prevalence and causes of vision loss in Indigenous and non-Indigenous Australians

191 Besides traction retinal detachment, vision loss in IP can occur with abnormalities of the in

192 Retinal cell death is the main cause of vision loss in many blinding conditions.

193 the normally avascular photoreceptors cause vision loss in many eye diseases, such as age-related ma

194 Photoreceptor death is the root cause of vision loss in many retinal disorders, and there is an u

195 ould be a risk factor for retinal damage and vision loss in nondiabetic as well as diabetic patients.

196 Sixty-five persons with AMD with evidence of vision loss in one or both eyes and 60 glaucoma suspects

197 s a common complication and a major cause of vision loss in patients with diabetes mellitus.

198 ive treatment to decrease the risk of severe vision loss in patients with proliferative diabetic reti

199 ible pharmacological approach that can delay vision loss in patients with RPE65 mutations.

200 herapeutic intervention that delays daylight vision loss in patients with RPE65 mutations.

201 tment and should be considered as a cause of vision loss in patients with this condition.

202 n lead to severe cone photoreceptor-mediated vision loss in patients.

203 tic retinopathy (DR) is important to prevent vision loss in persons with diabetes.

204 ally, PED emerged as trigger for consecutive vision loss in PRN treatment.

205 e cornea and can result in corneal edema and vision loss in severe cases.

206 developing brain that can lead to permanent vision loss in the affected eye.

207 ceptor survival, and is the leading cause of vision loss in the elderly.

208 ite populations, AMD is a prominent cause of vision loss in the nonindigenous Australian population.

209 presented with a 13-month history of gradual vision loss in the right eye to the extent that he could

210 It can contribute independently to vision loss in uveitic eyes.

211 Macular ischemia increased the risk of vision loss in vasculitis eyes by 4.4 times.

212 ) is a leading cause of irreversible, severe vision loss in Western countries.

213 displayed progressive gait abnormalities and vision loss, in addition to biochemical defects consiste

214 trated that baseline predictors for sporadic vision loss included worse baseline VA (OR 2.92, 95% con

215 blinding diseases that are characterized by vision loss, involuntary eye movement, and nonrecordable

216 Vision loss is among the first clinical signs in childho

217 Although vision loss is among the greatest fears of individuals w

218 f visual cortex plasticity following central vision loss is essential both for clarifying the mechani

219 Proper information on causes of childhood vision loss is essential in developing appropriate strat

220 Vision loss is more prevalent in Indigenous Australians

221 rly understood disease mechanisms, as severe vision loss is often associated both with defects in the

222 lammation with infiltrating neutrophils, and vision loss is potentially catastrophic.

223 ly good, but the true incidence of permanent vision loss is probably still underestimated.

224 s adapt eye movements in response to central vision loss is still not well understood and carries imp

225 No patient developed severe vision loss (</=15 letters) and vision was stable or imp

226 neration was attributed as the main cause of vision loss (<6/12 in the better eye) in 23 of 208 nonin

227 inopathy was attributed as the main cause of vision loss (<6/12 in the better eye) in 9% and 19% of n

228 itis is associated with an increased risk of vision loss, mainly secondary to macular ischemia, and h

229 These results suggest that central vision loss may give rise to cortical thinning, while in

230 ndilated examination, delayed-onset painless vision loss, mild anterior chamber and vitreous inflamma

231 ) develop neurodegeneration characterized by vision loss, motor dysfunction, seizures, and often earl

232 In cases when vision loss occurs, it is related mainly to retinal chan

233 ompt versus deferred laser groups, there was vision loss of >/=10 letters in 9% versus 8%, an improve

234 Of the included eyes, 90.5% avoided a vision loss of >/=15 letters.

235 complications associated with reoperation or vision loss of >2 Snellen lines occurred in 24 patients

236 Similarly, HRs of vision loss of 2 lines or more at 5 years for this degre

237 Therefore we examined the impact of central vision loss on motion perception using random dot kinema

238 , we explore the possible effects of central vision loss on the optimal saccades during a face identi

239 dinal population-based data on the effect of vision loss on vision-specific functioning (VSF) are sca

240 ular pressure (IOP) readings of <6 mmHg with vision loss or >17 mmHg without glaucoma medications (co

241 Glaucoma is a common cause of vision loss or blindness and reduction of intraocular pr

242 F by reverse transcriptase PCR, or (iii) new vision loss or hearing loss.

243 cades, scientists have dreamed of preventing vision loss or of restoring the vision of patients affec

244 n damage the retina, resulting in peripheral vision loss or worsening diabetic macular edema (DME).

245 raction decreased the likelihood of sporadic vision loss (OR 0.62, 95%CI: 0.42-0.91).

246 2 consecutive visits after 3 months, severe vision loss, or de novo glaucoma surgery.

247 amblyopia and a history of gradual bilateral vision loss over the previous 3 to 4 months.

248 asked about various possible consequences of vision loss, quality of life ranked as the top concern f

249 reafter laser control) eyes with substantial vision loss receiving treatment with intravitreal aflibe

250 reafter laser control) eyes with substantial vision loss receiving treatment with intravitreal aflibe

251 ignificantly reduces the incidence of severe vision loss related to macula-involving retinal detachme

252 f vision loss and to assess risk factors for vision loss, respectively.

253 s are required to delay or prevent avoidable vision loss resulting from DR in Indigenous Australian c

254 fter surgery, all eyes demonstrated painless vision loss resulting from HORV.

255 tocoagulation may help to prevent additional vision loss resulting from neovascular glaucoma.

256 t that its modulation could be used to treat vision loss secondary to corneal endothelial dysfunction

257 Vision loss secondary to corneal endothelial dysfunction

258 s of the listener's sightedness, duration of vision loss, sex, or age.

259 Vision loss should be anticipated in 45% by 5 years.

260 Refractive and nonrefractive vision loss should be distinguished in studies evaluatin

261 l model to predict where humans with central vision loss should direct their eye movements in face id

262 rations emerging after central or peripheral vision loss suggest that cerebral reorganization occurs

263 Eyes with retinopathy showed more severe vision loss than eyes without retinopathy.

264 onclusion, CLN5 deficient mice develop early vision loss that reflects the condition reported in clin

265 Both patients presented with vision loss that was initially thought to be optic neuri

266 Since glaucoma leads to irreversible vision loss, the present estimates of morbidity should b

267 ments for open-angle glaucoma aim to prevent vision loss through lowering of intraocular pressure, bu

268 In adult mice, vision loss through one eye instantly reduces neuronal a

269 rough the foveal center leads to significant vision loss through the availability of natural history

270 Cataracts cause vision loss through the large-scale aggregation of eye l

271 CI, 1.20-2.85; P = .005) were predictive of vision loss to a VA of less than 20/200.

272 th presented narrows down the cause of acute vision loss to the cone photoreceptor outer segment and

273 Vision loss (to visual acuity [VA] worse than 20/50 and

274 During follow-up 226 eyes (66%) experienced vision loss up to 20/50, but most recovered.

275 ence and main causes of bilateral presenting vision loss (visual acuity <6/12 in the better eye) were

276 The prevalence of vision loss was 11.2% (95% CI, 9.5-13.1) in Indigenous A

277 Vision loss was 2.8 times more prevalent in Indigenous A

278 (P = 0.001), respectively; that for moderate vision loss was 33% versus 57% (P < 0.001), respectively

279 2 years for those with and without sporadic vision loss was 58.5 ( approximately 20/63) and 68.4 ( a

280 apillary RNFL thickness in eyes experiencing vision loss was compared to eyes with stable vision.

281 Vision loss was defined as either a 0.2 logMAR decline i

282 As majority of the causes of vision loss was due to avoidable causes, we recommended

283 congenital anomaly, neoplasm, and hearing or vision loss was evaluated from birth to age 4 years.

284 The main reasons for postimplantation vision loss was glaucoma (12/31, 39%), and the risk of g

285 Vision loss was noted in 19.2% of eyes, with an incidenc

286 Over two-thirds (69.9%) of vision loss was potentially avoidable in nature.

287 The risk of vision loss was significantly more in the retinal vascul

288 The leading causes of vision loss were cataract (19.7%), corneal scars (15.7%)

289 gy, significant cataract, or nonglaucomatous vision loss were excluded.

290 Drivers with AMD-related vision loss were more likely to avoid driving over longe

291 d; glaucoma, macular degeneration, and other vision loss were overrepresented.

292 Contrast sensitivity and color vision loss were quantified.

293 ndigenous Australians, the leading causes of vision loss were uncorrected refractive error (60.8%), c

294 ndigenous Australians, the leading causes of vision loss were uncorrected refractive error (61.3%), c

295 The leading causes of vision loss were uncorrected refractive error and catara

296 e positive and negative predictive value for vision loss when 2 or more anatomic sectors were affecte

297 he posterior segment of the eye, can lead to vision loss when initiated by a virulent microbial patho

298 unchanged, some patients developed permanent vision loss, which may have resulted from inflammation a

299 Myopia is a common cause of vision loss, with uncorrected myopia the leading cause o

300 ma (POAG) is a leading cause of irreversible vision loss worldwide, with elevated intraocular pressur